Beta Bionics (NASDAQ:BBNX) Posts Earnings Results, Beats Estimates By $0.04 EPS

Beta Bionics (NASDAQ:BBNX) issued its quarterly earnings data on Tuesday. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04, FiscalAI reports. The firm had revenue of $27.63 million during the quarter. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%.

Here are the key takeaways from Beta Bionics’ conference call:

• Q1 revenue was $27.6 million (+57% YoY) and management raised full?year guidance to $131–136 million with gross margin guidance lifted to 57.5%–59.5%, signaling stronger-than-expected commercial traction and margin leverage.
• The pharmacy channel is accelerating — a high?30s% share of new patient starts went through pharmacy in Q1 (guidance 37%–39%) and the growing pharmacy installed base materially contributed to the 59.5% gross margin.
• Pipeline progress continues: the Mint patch pump remains on track for an unconstrained commercial launch by end of 2027 and the bi?hormonal program advanced into a Phase IIa feasibility trial.
• Operating expenses rose 47% YoY to $40.7 million due to salesforce expansion and R&D/marketing investments, and Q1 cash burn (~$25M) — despite about $240M in cash and investments — points to near?term pressure on free cash flow as investments ramp.
• The company is still remediating an FDA warning letter; while some corrective actions (e.g., complaint handling) were completed early, management says additional work remains, representing ongoing regulatory risk.

Beta Bionics Price Performance

BBNX opened at $12.27 on Wednesday. The company’s 50-day moving average is $11.59 and its 200 day moving average is $19.98. Beta Bionics has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The firm has a market capitalization of $546.75 million, a P/E ratio of -6.29 and a beta of 5.06.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Values First Advisors Inc. lifted its position in shares of Beta Bionics by 35.1% during the first quarter. Values First Advisors Inc. now owns 47,551 shares of the company’s stock valued at $476,000 after purchasing an additional 12,360 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in Beta Bionics by 1,075.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after acquiring an additional 1,818 shares during the period. Invesco Ltd. raised its position in Beta Bionics by 140.9% in the fourth quarter. Invesco Ltd. now owns 117,360 shares of the company’s stock worth $3,576,000 after acquiring an additional 68,640 shares during the period. XTX Topco Ltd bought a new stake in Beta Bionics in the fourth quarter worth about $1,340,000. Finally, Voloridge Investment Management LLC raised its position in Beta Bionics by 549.6% in the fourth quarter. Voloridge Investment Management LLC now owns 151,647 shares of the company’s stock worth $4,621,000 after acquiring an additional 128,301 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on BBNX shares. Robert W. Baird reduced their price objective on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. The Goldman Sachs Group reduced their price objective on shares of Beta Bionics from $23.00 to $20.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a report on Friday, March 27th. Truist Financial reduced their price objective on shares of Beta Bionics from $25.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. Finally, Bank of America cut shares of Beta Bionics from a “buy” rating to a “neutral” rating in a report on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $22.00.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.